Company intelligence / Profile preview

BrYet Health

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

Preclinical studies demonstrated unprecedented efficacy, with ~50% long-term survival in otherwise uniformly lethal metastatic models. First-in-human Phase 1/2 trial of ML-016 (amino acid polymer-doxorubicin conjugate with mesoporous silicon carriers) in patients with advanced metastatic cancers involving lung or liver starts in 2026. Initial human data pending.

Therapeutic areas: Oncology
Modalities: Polymer-drug conjugate therapySmall molecule
Industry: Biotech

Partnerships

NerPharMa (manufacturing partner)

Beyond the preview

Go deeper on BrYet Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrYet Health.

Explore the full profile